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Abstract
Disseminated disease caused by Mycobacterium simiae, a slowly
growing nontuberculous mycobacterium, has been rarely
reported in the literature. We report on three AIDS patients
who were found to suffer from mycobacteraemia caused by
M. simiae in a rural tertiary-care hospital in central India.
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Mycobacterium simiae is a nontuberculous mycobacterium
that was described in 1965 as a novel species in Macaca rhe-
sus monkeys imported from India [1]. The ﬁrst human case
was reported in 1971 and, subsequently, M. simiae has been
regularly isolated from clinical samples in sporadic cases in
areas including the southwestern United States (Texas, New
Mexico and Arizona), Israel and the Caribbean, including
Cuba [2–5]. Clinical disease caused by M. simiae is similar to
that caused by Mycobacterium avium intracellulare complex
(MAC) and includes chronic pulmonary disease, osteomyelitis
and disseminated disease [6]. Disseminated disease is rare
and presents as mycobacteraemia, mainly in AIDS patients
and certain patients in other immunodeﬁciency states [7–11].
In India, this organism was not reported in clinical samples
for a long period. In a previous study from our centre con-
ducted in 2002–2003 M. simiae was isolated from the blood
of AIDS patients [12]. Because it is a rare entity, we report
on three cases with disseminated M. simiae disease who pre-
sented at a rural tertiary-care hospital in Central India during
2005–2006.
All three patients were known HIV seropositive patients
with low CD4 counts (<100 cells/mm3) who presented with
a history of fever, breathlessness and weight loss. The
important clinical features and laboratory data are presented
in Table 1.
Blood cultures were performed for these patients, as part
of an ongoing approved study, using BACTEC 13A medium
and the BACTEC 460TB system (Becton-Dickinson Bio-
sciences, Franklin Lakes, NJ, USA) according to standard pro-
cedures. Plates of blood agar and chocolate agar were
inoculated to rule out concomitant infection along with that
caused by mycobacteria. The mycobacterial isolates were
identiﬁed using phenotypic methods [13] and conﬁrmed by
PCR and restriction enzyme analysis [14] and by 16SrRNA
gene sequencing [15]. Blood samples of these patients
yielded M. simiae. Drug susceptibility to streptomycin, isonia-
zid, rifampicin, ethambutol, oﬂoxacin and kanamycin was
tested by determining MICs using the microtitre plate
method in accordance with CLSI guidelines [16]. The MIC
values are presented in Table 2.
TABLE 1. Clinical features of three patients with dissemi-
nated Mycobacterium simiae disease
Feature Patient 1 Patient 2 Patient 3
Age/sex 27 years/female 40 years/male 46 years/male
Fever Present 3 days Present 1 year Present 1 year
Breathlessness Present Present Present
Cough Present Absent Absent
Loss of weight Present Present Present
Night sweats Present Absent Absent
Diarrhoea Present Absent Absent
Body mass index 13.9 17.4 19.2
Hepatomegaly Present Absent Absent
CD4 cells/mm3 116 78 80
CD8 cells/mm3 669 791 465
Chest X-ray Pleural effusion Normal Normal
Blood culture Mycobacterium
simiae
Mycobacterium
simiae
Mycobacterium
simiae
Stool culture Mycobacterium simiae No growth No growth
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Along with blood samples, two stool samples were also
processed for isolation of mycobacteria. Three sputum sam-
ples were processed if the patient had productive cough.
The stool sample from one patient yielded M. simiae. The
MIC for this isolate was the same as that for the blood iso-
late from the same patient.
All patients were referred to the Antiretroviral Therapy
(ART) center located 80 km from our hospital, immediately
after their CD4 counts were available. Anti-tuberculosis
treatment was started for Patient 1 (Table 1). However, all
patients were lost to follow up by the time the diagnosis of
M. simiae infection was established.
M. simiae, similar to other nontuberculous mycobacteria,
enters the human body either via inhalation or ingestion and
may colonize the respiratory tract or the gut. Depending
upon the immune status of the patient, it may be eradicated
or multiply at the primary sites. If the CD4 counts are
<100 cells/mm3, these mycobacteria invade the blood stream
and reach sites distant from their initial focus [17].
In the present study, in at least one patient, we had some
indication of the possible route of entry of M. simiae because
the MICs for both isolates, from blood and stool, were the
same.
All three patients had fever which is an indicator of bac-
teraemia. With respect to nontuberculous mycobacteria, this
aspect has been studied in detail in disseminated MAC dis-
ease, which characteristically occurs in patients with very
advanced HIV disease and when peripheral blood CD4
T-lymphocyte counts fall below 100 cells/mm3.
However, disseminated disease caused by M. simiae has
not been commonly reported in the literature. As is the case
with infections caused by other nontuberculous mycobacte-
ria, AIDS and presumably other immunodeﬁciencies are also
risk factors for M. simiae infection [10]. In another study per-
formed at our center during 2002, blood samples from 71
out of 167 patients who tested positive for HIV were cul-
tured for mycobacteria. Sixty-seven of these patients were
clinically diagnosed as cases of pulmonary and/or extrapul-
monary tuberculosis. MAC was isolated from blood of three
patients (4.2%) and M. simiae from another three. No
Mycobacterium tuberculosis was isolated from blood [12]. In
these patients fever was also the common symptom.
In the world literature, there are other reports of dissem-
inated disease caused by M. simiae [7–10]. In Berlin, M. simiae
was recovered from one of 16 AIDS patients who suffered
from nontuberculous mycobacterial infections [6]. Four HIV-
infected patients from Thailand and Malawi who were
infected with M. simiae–M. avium group (SAV group) organ-
isms have been described in the literature. These infections
were detected during prospective blood culture studies of
febrile, adult HIV-positive inpatients in these two countries
[18].
Exposure to possible environmental sources of M. simiae
or to an animal or a person infected with M. simiae may be a
risk factor for infection [1]. Residence in a particular
geographical location may also be a risk factor for M. simiae
infection because isolation appears to be restricted to a few
regions of the world.
Isolation of M. simiae from tap water samples in certain
geographical areas has been reported [6]. The natural habi-
tat of M. simiae, and the mechanism of its transmission to
animals and humans, are still not clearly identiﬁed. M. simiae
has been recovered from hospital water supplies [8,19,20],
as well as from sphagnum vegetations of Madagascar [21].
In India however, M. simiae has not been isolated from the
environment [22–24], including the place of residence of
the three patients of the present study (R. Narang, Charac-
terization of nontuberculous mycobacterial isolates from
HIV seropositive patients attending a rural hospital and
their correlation with environmental isolates. PhD thesis
submitted to RTM Nagpur University, Nagpur 2007; unpub-
lished data).
Treatment options for patients with disseminated M. simiae
disease are limited. Treatment success has been reported with
highly active antiretroviral therapy combined with a regimen of
clarithromycin, ethambutol and ciproﬂoxacin [22–25]. How-
TABLE 2. MICs (mg/L) of six drugs
for Mycobacterium simiae isolates
Sample Isolate Streptomycin Isoniazid Rifampicin Ethambutol Kanamycin Oﬂoxacin
Patient 1 blood Mycobacterium
simiae
>64 R >16 R >16 R >64 R >64 R >64 R
Patient 1 stool Mycobacterium
simiae
64 R >16 R >16 R >64 R >64 R >64 R
Patient 2 blood Mycobacterium
simiae
8 MR >16 R 16 R 8 MR >64 R >64 R
Patient 3 blood Mycobacterium
simiae
>64 R >16 R >16 R >64 R >64 R >64 R
MR, moderately resistant; R, resistant. Cut-off titres are in accordance with CLSI (2003) criteria.
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ever, all four isolates of M. simiae in the present study showed
in vitro resistance to ethambutol and oﬂoxacin.
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